Anixa Biosciences (ANIX) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Anixa Biosciences (ANIX) has outperformed Upstream Bio (UPB) over the past year, losing 43.8% versus a loss of 93.8%. Upstream Bio is the larger company by market cap ($87.2 million vs $84.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | UPB |
|---|---|---|
| Share price | $2.44 | $1.59 |
| Market cap | $84.82M | $87.15M |
| 1-day change | -6.15% | -20.50% |
| YTD return | -21.79% | -94.14% |
| 1-year return | -43.78% | -93.78% |
| 5-year return | -38.69% | — |
| EPS (TTM) | $-0.32 | $-3.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.85M |
| Revenue growth (YoY) | — | +20.42% |
| Net income (latest FY) | $-10.93M | $-143.44M |
| Operating margin | — | -5618.82% |
| Net margin | — | -5026.03% |
| 52-week high | $5.46 | $33.68 |
| 52-week low | $2.32 | $1.56 |
| Distance from 52-week high | -55.31% | -95.28% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +296.31% | +1245.91% |
| Average volume | 282.29K | 1.01M |
| Shares outstanding | 34.76M | 54.81M |
| Employees | 4 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIX has outperformed UPB by 50.0 percentage points over the past year.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
ANIX vs UPB FAQ
Which is bigger, Anixa Biosciences or Upstream Bio?
Upstream Bio (UPB) is larger, with a market capitalization of $87.15M compared with $84.82M for Anixa Biosciences (ANIX).
Which stock has performed better over the past year, ANIX or UPB?
ANIX returned -43.78% over the past 12 months, compared with -93.78% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.